Particle Therapy 2017

‹#›

Proton Therapy for

Stage II-III Non-Small-Cell Lung Cancer (NSCLC):

3 prospective, multicenter trials in the USA

●

Phase III Trial initiated by MGH/MDACC photons versus protons to 74 Gy

(completed accrual)

●

Phase III RTOG trial photons versus protons to 70Gy or lower as per strict

OAR constraints (open)

●

Phase II hypofractionated dose escalation trial 60 Gy at 25 Gy/frct up to 4

Gy/frct– Univ. Florida PTC (open for accrual)

Prospective trials in Europe

●

PRONTOX. Single-center

, randomized Phase II. Photons vrs. protons. 66 Gy

(RBE) (2 Gy x 6 per week) with concomitant chemotherapy. Primary endpoint:

Reduction of radiation-induced side effects (esophagitis and pneumonitis grade II

or higher) from 39 to 12% by protons. Univ. Dresden, Germany